News

Cell Medica raises €21,7m
Enlarge image

BusinessUK

Cell Medica raises €21,7m

24.07.2012 - London-based biotech company Cell Medica, developing cell-based therapeutics, has closed a £17m (€21,7m) funding round.

The financing includes a significant contribution from a Texan state fund called The Cancer Prevention and Research Institute of Texas (CPRIT). Cell Medica is to begin new operations in Texas focused on cancer immunotherapy as a result of the funding, which will also finance ongoing immune reconstitution studies in Europe.

CPRIT is committing £9.7m (€12,4m) to Cell Medica, enabling it conduct US clinical development of its Cytorex EBV therapy to treat cancers associated with Epstein Barr virus. In Europe, the company's Cytovir technologies are being developed for the treatment of life-threatening viral infections in lymphoma and leukaemia patients who have undergone bone marrow transplants. The company hopes to launch its Cytovir therapy for cytomegalovirus in Europe next year following completion of two ongoing studies in the UK. Other investors include Invesco Perpetual (£4m or €5,1m) and Imperial Innovations (£3m, €3,8m). The Wellcome Trust also becomes a shareholder in the company through conversion of a loan security into equity. Cell Medica uses its technology to select, activate and expand T-cells to treat a range of indications. The firm has additionally appointed Thomas Hecht, a former transplant physician and previous senior executive in Amgen's European Operation, as chairman.

http://www.european-biotechnology-news.com/news/news/2012-03/cell-medica-raises-eur217m.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.21 EUR3.69%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%

FLOP

  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%

TOP

  • WILEX4.21 EUR419.8%
  • CYTOS0.63 CHF350.0%
  • 4SC4.65 EUR322.7%

FLOP

  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.89 EUR-21.3%

No liability assumed, Date: 23.05.2015